Sanofi stops development of Nurix-partnered immune drug

Coverage, in order

1. 7d ago
   
   BioPharma Dive indie

   Sanofi stops development of Nurix-partnered immune drug

   The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.